{"transactions":[{"id":695484,"issuer":{"id":4350,"kind":"organization","name":"Prestige Consumer Healthcare Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2026-08-05T20:07:41.000Z","date":"2026-08-04","kind":"grant","planned":false,"acquired":true,"shares":2981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received 2,981 restricted stock units equal to $155,000 divided by the closing stock price of $52.00 on August 4, 2026, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control."}],"balance_after":9572,"source":{"system":"sec-edgar","filing":"0001104659-26-091082","document":"tm2622318-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1295947/000110465926091082/tm2622318-3_4seq1.xml","form_type":"4"}},{"id":773863,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-19T21:34:54.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":29312,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":54444,"source":{"system":"sec-edgar","filing":"0000313143-26-000046","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000031314326000046/form4.xml","form_type":"4"}},{"id":773862,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-19T21:34:54.000Z","date":"2026-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":2505,"price":56.29,"value":141006.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":25132,"source":{"system":"sec-edgar","filing":"0000313143-26-000046","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000031314326000046/form4.xml","form_type":"4"}},{"id":793018,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T20:24:48.000Z","date":"2026-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":655,"price":59.26,"value":38815.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":27637,"source":{"system":"sec-edgar","filing":"0000313143-26-000026","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000031314326000026/form4.xml","form_type":"4"}},{"id":1073045,"issuer":{"id":4350,"kind":"organization","name":"Prestige Consumer Healthcare Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2025-08-06T20:02:58.000Z","date":"2025-08-05","kind":"grant","planned":false,"acquired":true,"shares":2094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received 2,094 restricted stock units equal to $155,000 divided by the closing stock price of $674.04 on August 5, 2025, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control."}],"balance_after":6591,"source":{"system":"sec-edgar","filing":"0001104659-25-074702","document":"tm2522759-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1295947/000110465925074702/tm2522759-3_4seq1.xml","form_type":"4"}},{"id":1126650,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-03T20:35:07.000Z","date":"2025-05-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":5864,"price":69.38,"value":406844.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested restricted stock units (\"RSUs\") previously reported."}],"balance_after":28292,"source":{"system":"sec-edgar","filing":"0001127602-25-016517","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760225016517/form4.xml","form_type":"4"}},{"id":1126649,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-03T20:35:07.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":12221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned from a performance share unit (\"PSU\") award granted to the reporting person on May 16, 2022, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 16, 2022 to May 15, 2025, as certified by the Compensation Committee of the Board of Directors on May 30, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested restricted stock units (\"RSUs\") previously reported."}],"balance_after":34156,"source":{"system":"sec-edgar","filing":"0001127602-25-016517","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760225016517/form4.xml","form_type":"4"}},{"id":1141350,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2025-05-20T21:14:18.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":15396,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option vests in annual increments of 25% beginning on the first anniversary of the date of grant."}],"balance_after":15396,"derivative":{"exercise_price":70.31,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":15396},"source":{"system":"sec-edgar","filing":"0001127602-25-015054","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760225015054/form4.xml","form_type":"4"}},{"id":1141349,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T21:14:18.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":7111,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units (\"RSUs\") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes unvested RSUs previously reported."}],"balance_after":21935,"source":{"system":"sec-edgar","filing":"0001127602-25-015054","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760225015054/form4.xml","form_type":"4"}},{"id":1144263,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-19T21:15:15.000Z","date":"2025-05-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":1246,"price":70.31,"value":87606.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":14824,"source":{"system":"sec-edgar","filing":"0001127602-25-014944","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760225014944/form4.xml","form_type":"4"}},{"id":1144262,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-19T21:15:15.000Z","date":"2025-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":622,"price":69.38,"value":43154.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":16070,"source":{"system":"sec-edgar","filing":"0001127602-25-014944","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760225014944/form4.xml","form_type":"4"}},{"id":1160311,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-05T20:16:09.000Z","date":"2025-05-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":654,"price":63.85,"value":41757.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":16692,"source":{"system":"sec-edgar","filing":"0001127602-25-013343","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760225013343/form4.xml","form_type":"4"}},{"id":1438690,"issuer":{"id":4350,"kind":"organization","name":"Prestige Consumer Healthcare Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2024-08-07T20:04:50.000Z","date":"2024-08-06","kind":"grant","planned":false,"acquired":true,"shares":2202,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received 2,202 restricted stock units equal to $150,000 divided by the closing stock price of $68.13 on August 6, 2024, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control."}],"balance_after":4497,"source":{"system":"sec-edgar","filing":"0001104659-24-086748","document":"tm2421115-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1295947/000110465924086748/tm2421115-5_4seq1.xml","form_type":"4"}},{"id":1508129,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2024-05-21T21:41:53.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":9756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option vests in annual increments of 25% beginning on the first anniversary of the date of grant."}],"balance_after":9756,"derivative":{"exercise_price":95.73,"expiration_date":"2031-05-17","underlying":"Common Stock","underlying_shares":9756},"source":{"system":"sec-edgar","filing":"0001127602-24-016162","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760224016162/form4.xml","form_type":"4"}},{"id":1508128,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-21T21:41:53.000Z","date":"2024-05-17","kind":"grant","planned":false,"acquired":true,"shares":4439,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units (\"RSUs\") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes unvested RSUs previously reported."}],"balance_after":17346,"source":{"system":"sec-edgar","filing":"0001127602-24-016162","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760224016162/form4.xml","form_type":"4"}},{"id":1513263,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T20:52:28.000Z","date":"2024-05-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":351,"price":94.8,"value":33274.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":12907,"source":{"system":"sec-edgar","filing":"0001127602-24-015864","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760224015864/form4.xml","form_type":"4"}},{"id":1513262,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-17T20:52:28.000Z","date":"2024-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":412,"price":96.49,"value":39753.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":13258,"source":{"system":"sec-edgar","filing":"0001127602-24-015864","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760224015864/form4.xml","form_type":"4"}},{"id":1526980,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-06T20:19:15.000Z","date":"2024-05-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":432,"price":93.33,"value":40318.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":13670,"source":{"system":"sec-edgar","filing":"0001127602-24-014274","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760224014274/form4.xml","form_type":"4"}},{"id":1816146,"issuer":{"id":4350,"kind":"organization","name":"Prestige Consumer Healthcare Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01 per share","published_at":"2023-08-03T18:01:43.000Z","date":"2023-08-01","kind":"grant","planned":false,"acquired":true,"shares":2295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received 2,295 restricted stock units equal to $150,000 divided by the closing stock price of $65.37 on August 1, 2023, in connection with the Issuer's director compensation program. The restricted stock units vest on the first anniversary of grant and will be settled by delivery to the Reporting Person of one share of common stock of the issuer for each vested restricted stock unit promptly following the earliest of (1) the Reporting Person's death, (ii) the Reporting Person's separation or (iii) change in control."}],"balance_after":2295,"source":{"system":"sec-edgar","filing":"0001104659-23-087189","document":"tm2322776-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1295947/000110465923087189/tm2322776-3_4seq1.xml","form_type":"4"}},{"id":1890588,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2023-05-17T20:26:31.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":9502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Option vests in annual increments of 25% beginning on the first anniversary of the date of grant."}],"balance_after":9502,"derivative":{"exercise_price":89.16,"expiration_date":"2030-05-15","underlying":"Common Stock","underlying_shares":9502},"source":{"system":"sec-edgar","filing":"0001127602-23-015929","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760223015929/form4.xml","form_type":"4"}},{"id":1890587,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-17T20:26:31.000Z","date":"2023-05-16","kind":"tax_withholding","planned":false,"acquired":false,"shares":349,"price":89.21,"value":31134.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes unvested RSUs previously reported."}],"balance_after":14102,"source":{"system":"sec-edgar","filing":"0001127602-23-015929","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760223015929/form4.xml","form_type":"4"}},{"id":1890586,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-17T20:26:31.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":4205,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units (\"RSUs\") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes unvested RSUs previously reported."}],"balance_after":14451,"source":{"system":"sec-edgar","filing":"0001127602-23-015929","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760223015929/form4.xml","form_type":"4"}},{"id":1905148,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-04T20:27:00.000Z","date":"2023-05-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":430,"price":81.66,"value":35113.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units (\"RSUs\") previously reported in Table I."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes unvested RSUs previously reported."}],"balance_after":10246,"source":{"system":"sec-edgar","filing":"0001127602-23-014489","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760223014489/form4.xml","form_type":"4"}},{"id":2266984,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2022-05-18T20:34:44.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":11163,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option vests in annual increments of 25% beginning on the first anniversary of the date of grant."}],"balance_after":11163,"derivative":{"exercise_price":57.6,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":11163},"source":{"system":"sec-edgar","filing":"0001127602-22-014966","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760222014966/form4.xml","form_type":"4"}},{"id":2266983,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-18T20:34:44.000Z","date":"2022-05-16","kind":"grant","acquired":true,"shares":4774,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units (\"RSUs\") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number includes unvested RSUs previously reported."}],"balance_after":10676,"source":{"system":"sec-edgar","filing":"0001127602-22-014966","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760222014966/form4.xml","form_type":"4"}},{"id":2283309,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Non-qualified Stock Option (Right to Buy)","published_at":"2022-05-04T20:41:13.000Z","date":"2022-05-02","kind":"grant","acquired":true,"shares":13828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests in annual increments of 25% beginning on the first anniversary of the date of grant."}],"balance_after":13828,"derivative":{"exercise_price":50.83,"expiration_date":"2029-05-02","underlying":"Common Stock","underlying_shares":13828},"source":{"system":"sec-edgar","filing":"0001127602-22-013206","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760222013206/form4.xml","form_type":"4"}},{"id":2283308,"issuer":{"id":3953,"kind":"organization","name":"HAEMONETICS CORP"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"officer":true,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-05-04T20:41:13.000Z","date":"2022-05-02","kind":"grant","acquired":true,"shares":5902,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units (\"RSUs\") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested."}],"balance_after":5902,"source":{"system":"sec-edgar","filing":"0001127602-22-013206","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/313143/000112760222013206/form4.xml","form_type":"4"}},{"id":2606316,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-08-13T01:33:45.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":217167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."},{"field":"shares","element":"transactionShares","label":"F4","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"Each RSU represents a contingent right to receive one share of issuer common stock upon settlement."}],"balance_after":434333,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":217167},"source":{"system":"sec-edgar","filing":"0001387131-21-008437","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121008437/ownership.xml","form_type":"4"}},{"id":2606315,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-13T01:33:45.000Z","date":"2021-08-12","kind":"sale","acquired":false,"shares":93337,"price":0.87,"value":81203.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $0.87 to $0.88. The price reported in Column 4 reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":123830,"source":{"system":"sec-edgar","filing":"0001387131-21-008437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121008437/ownership.xml","form_type":"4"}},{"id":2606314,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-13T01:33:45.000Z","date":"2021-08-10","kind":"exercise","acquired":true,"shares":217167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 10, 2021, the reporting person received 217,167 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021."}],"balance_after":217167,"source":{"system":"sec-edgar","filing":"0001387131-21-008437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121008437/ownership.xml","form_type":"4"}},{"id":2646978,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted Stock Units","published_at":"2021-07-02T21:45:52.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":173333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024."}],"balance_after":173333,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":173333},"source":{"system":"sec-edgar","filing":"0001387131-21-007115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121007115/ownership.xml","form_type":"4"}},{"id":2646977,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Performance Stock Units","published_at":"2021-07-02T21:45:52.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":346667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":346667,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":346667},"source":{"system":"sec-edgar","filing":"0001387131-21-007115","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713121007115/ownership.xml","form_type":"4"}},{"id":3065465,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-08-08T01:16:32.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":651500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023."}],"balance_after":651500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":651500},"source":{"system":"sec-edgar","filing":"0001387131-20-007227","document":"darecca-form4a_061820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120007227/darecca-form4a_061820.xml","form_type":"4/A","original_submission_date":"2020-06-19"}},{"id":3065464,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2020-08-08T01:16:32.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":151500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on when the issuer achieves break-even of quarterly EBITDA. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":151500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":151500},"source":{"system":"sec-edgar","filing":"0001387131-20-007227","document":"darecca-form4a_061820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120007227/darecca-form4a_061820.xml","form_type":"4/A","original_submission_date":"2020-06-19"}},{"id":3104958,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-06-19T21:07:01.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":651500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning June 1, 2021 (the one-year anniversary of the date of the reporting person's appointment as Chief Financial Officer), becoming fully vested on June 1, 2023."}],"balance_after":651500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":651500},"source":{"system":"sec-edgar","filing":"0001387131-20-005814","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120005814/ownership.xml","form_type":"4"}},{"id":3104957,"issuer":{"id":7541,"kind":"organization","name":"TherapeuticsMD, Inc."},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2020-06-19T21:07:01.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":151500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The performance stock units (PSUs) vest upon the issuer achieving break-even of quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) for a fiscal quarter no later than the quarter ending December 31, 2022, otherwise the PSUs will be forfeited. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":151500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":151500},"source":{"system":"sec-edgar","filing":"0001387131-20-005814","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/25743/000138713120005814/ownership.xml","form_type":"4"}},{"id":3153969,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Performance Stock Units","published_at":"2020-05-11T21:50:53.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":3534,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Reflects the disposition of performance stock units relating to Allergan Shares (\"Allergan PSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, was substituted by AbbVie with an AbbVie restricted stock unit award relating to shares of AbbVie common stock, that vests based on the holder's continued service following the effective time of the Scheme, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formulas set forth in the Transaction Agreement (which, for any Allergan performance stock unit awards that were subject to performance-based vesting conditions on June 25, 2019, was calculated based on deemed satisfaction of performance at 130% of target)."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":3534},"source":{"system":"sec-edgar","filing":"0000899243-20-012758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000089924320012758/doc4.xml","form_type":"4"}},{"id":3153968,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Stock Options","published_at":"2020-05-11T21:50:53.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":4957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":224,"expiration_date":"2023-07-17","underlying":"Ordinary Shares","underlying_shares":4957},"source":{"system":"sec-edgar","filing":"0000899243-20-012758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000089924320012758/doc4.xml","form_type":"4"}},{"id":3153967,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Stock Options","published_at":"2020-05-11T21:50:53.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":1169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"All of the stock options to purchase Allergan Shares (\"Allergan Options\") were vested as of May 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Reflects the disposition of Allergan Options as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Option was substituted by AbbVie with a corresponding AbbVie stock option relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such stock option and the exercise price per share applicable to such stock option determined in accordance with the formulas set forth in the Transaction Agreement."}],"balance_after":0,"derivative":{"exercise_price":296.14,"expiration_date":"2023-07-17","underlying":"Ordinary Shares","underlying_shares":1169},"source":{"system":"sec-edgar","filing":"0000899243-20-012758","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000089924320012758/doc4.xml","form_type":"4"}},{"id":3153966,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Restricted Stock Units","published_at":"2020-05-11T21:50:53.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":6324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the disposition of restricted stock units relating to Allergan Shares (\"Allergan RSUs\") as contemplated by the Transaction Agreement.  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan RSU was substituted by AbbVie with a corresponding AbbVie restricted stock unit award relating to shares of AbbVie common stock, with the number of shares of AbbVie common stock subject to such award determined in accordance with the formula set forth in the Transaction Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-012758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000089924320012758/doc4.xml","form_type":"4"}},{"id":3153965,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-05-11T21:50:53.000Z","date":"2020-05-08","kind":"disposition_to_issuer","acquired":false,"shares":3511,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the disposition of ordinary shares (\"Allergan Shares\") of Allergan plc (\"Allergan\") as contemplated by the Transaction Agreement dated as of June 25, 2019 among AbbVie Inc. (\"AbbVie\"), Venice Subsidiary, LLC (\"Acquirer Sub\") and Allergan (the \"Transaction Agreement\"), pursuant to which Acquirer Sub acquired Allergan pursuant to a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act of 2014 and the capital reduction under Sections 84 and 85 of the Act (the \"Scheme\").  In accordance with the terms of the Transaction Agreement, at the effective time of the Scheme, each Allergan Share was converted into $120.30 in cash and 0.8660 of a newly issued share of AbbVie common stock, par value $0.01 per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-012758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000089924320012758/doc4.xml","form_type":"4"}},{"id":3217136,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-03-10T14:10:04.000Z","date":"2020-03-06","kind":"tax_withholding","acquired":false,"shares":718,"price":191.95,"value":137820.1,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc."}],"balance_after":9834,"source":{"system":"sec-edgar","filing":"0000899243-20-007719","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000089924320007719/doc4.xml","form_type":"4"}},{"id":3226440,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-03-04T14:22:35.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":3611,"price":193.84,"value":699956.24,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the Amended and Restated 2013 Incentive Award Plan of Allergan plc."}],"balance_after":10552,"source":{"system":"sec-edgar","filing":"0001179110-20-003042","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911020003042/edgar.xml","form_type":"4"}},{"id":3326622,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2020-01-02T17:52:36.000Z","date":"2019-12-31","kind":"tax_withholding","acquired":false,"shares":92,"price":191.17,"value":17587.64,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":6941,"source":{"system":"sec-edgar","filing":"0001179110-20-000043","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911020000043/edgar.xml","form_type":"4"}},{"id":3601167,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-03-11T17:49:12.000Z","date":"2019-03-08","kind":"tax_withholding","acquired":false,"shares":113,"price":145.06,"value":16391.78,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":7033,"source":{"system":"sec-edgar","filing":"0001179110-19-003702","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911019003702/edgar.xml","form_type":"4"}},{"id":3601166,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-03-11T17:49:12.000Z","date":"2019-03-07","kind":"tax_withholding","acquired":false,"shares":359,"price":143,"value":51337.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":7146,"source":{"system":"sec-edgar","filing":"0001179110-19-003702","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911019003702/edgar.xml","form_type":"4"}},{"id":3603679,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-03-08T15:27:34.000Z","date":"2019-03-06","kind":"grant","acquired":true,"shares":2036,"price":137.51,"value":279970.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 6, 2020, twenty-five percent (25%) on March 6, 2021, twenty-five percent (25%) on March 6, 2022 and twenty-five percent (25%) on March 6, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":7505,"source":{"system":"sec-edgar","filing":"0001179110-19-003597","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911019003597/edgar.xml","form_type":"4"}},{"id":3607799,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-03-06T15:49:12.000Z","date":"2019-03-04","kind":"tax_withholding","acquired":false,"shares":114,"price":139.12,"value":15859.68,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":5469,"source":{"system":"sec-edgar","filing":"0001179110-19-003412","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911019003412/edgar.xml","form_type":"4"}},{"id":3607791,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-03-06T15:48:37.000Z","date":"2018-03-07","kind":"grant","acquired":true,"shares":1826,"price":153.22,"value":279779.72,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amended Form 4 includes 130 restricted share units related to the March 7, 2018 grant, which were inadvertently omitted from the Form 4 filed by the Reporting Person on March 8, 2018. The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 7, 2019, twenty-five percent (25%) on March 7, 2020, twenty-five percent (25%) on March 7, 2021 and twenty-five percent (25%) on March 7, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted stock units issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":5809,"source":{"system":"sec-edgar","filing":"0001179110-19-003411","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911019003411/edgar.xml","form_type":"4/A","original_submission_date":"2018-03-08"}},{"id":3707428,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2019-01-03T15:50:55.000Z","date":"2018-12-31","kind":"tax_withholding","acquired":false,"shares":147,"price":133.66,"value":19648.02,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":5453,"source":{"system":"sec-edgar","filing":"0001179110-19-000195","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911019000195/edgar.xml","form_type":"4"}},{"id":4002725,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-03-09T16:34:38.000Z","date":"2018-03-08","kind":"tax_withholding","acquired":false,"shares":79,"price":153.5,"value":12126.5,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":5600,"source":{"system":"sec-edgar","filing":"0001179110-18-003970","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911018003970/edgar.xml","form_type":"4"}},{"id":4004877,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-03-08T16:16:15.000Z","date":"2018-03-07","kind":"grant","acquired":true,"shares":1696,"price":153.22,"value":259861.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 7, 2019, twenty-five percent (25%) on March 7, 2020, twenty-five percent (25%) on March 7, 2021 and twenty-five percent (25%) on March 7, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":5679,"source":{"system":"sec-edgar","filing":"0001179110-18-003856","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911018003856/edgar.xml","form_type":"4"}},{"id":4004876,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-03-08T16:16:15.000Z","date":"2018-03-07","kind":"tax_withholding","acquired":false,"shares":93,"price":153.22,"value":14249.46,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":3983,"source":{"system":"sec-edgar","filing":"0001179110-18-003856","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911018003856/edgar.xml","form_type":"4"}},{"id":4009820,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-03-06T18:53:56.000Z","date":"2018-03-05","kind":"tax_withholding","acquired":false,"shares":70,"price":148.73,"value":10411.1,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":4076,"source":{"system":"sec-edgar","filing":"0001179110-18-003679","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911018003679/edgar.xml","form_type":"4"}},{"id":4009819,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-03-06T18:53:56.000Z","date":"2018-03-02","kind":"tax_withholding","acquired":false,"shares":76,"price":144.02,"value":10945.52,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":4146,"source":{"system":"sec-edgar","filing":"0001179110-18-003679","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911018003679/edgar.xml","form_type":"4"}},{"id":4116799,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2018-01-02T16:40:35.000Z","date":"2017-12-29","kind":"tax_withholding","acquired":false,"shares":100,"price":163.58,"value":16358.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":4222,"source":{"system":"sec-edgar","filing":"0001179110-18-000117","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911018000117/edgar.xml","form_type":"4"}},{"id":4178307,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Performance Based Restricted Share Unit","published_at":"2017-10-30T21:19:57.000Z","date":"2017-10-26","kind":"exercise","acquired":false,"shares":799,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":799},"source":{"system":"sec-edgar","filing":"0001179110-17-013549","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017013549/edgar.xml","form_type":"4"}},{"id":4178306,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-10-30T21:19:57.000Z","date":"2017-10-26","kind":"exercise","acquired":true,"shares":799,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest in equal installments on each of December 31, 2017, December 31, 2018 and December 31, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Performance Based Restricted Share Unit or PSU represented a contingent right to receive a number of Ordinary Shares equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":4322,"source":{"system":"sec-edgar","filing":"0001179110-17-013549","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017013549/edgar.xml","form_type":"4"}},{"id":4392109,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-03-09T17:53:12.000Z","date":"2017-03-08","kind":"tax_withholding","acquired":false,"shares":77,"price":239.44,"value":18436.88,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":3523,"source":{"system":"sec-edgar","filing":"0001179110-17-004353","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017004353/edgar.xml","form_type":"4"}},{"id":4392108,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-03-09T17:53:12.000Z","date":"2017-03-07","kind":"grant","acquired":true,"shares":1085,"price":239.6,"value":259966.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 7, 2018, twenty-five percent (25%) on March 7, 2019, twenty-five percent (25%) on March 7, 2020 and twenty-five percent (25%) on March 7, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":3600,"source":{"system":"sec-edgar","filing":"0001179110-17-004353","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017004353/edgar.xml","form_type":"4"}},{"id":4396614,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-03-07T16:54:19.000Z","date":"2017-03-05","kind":"tax_withholding","acquired":false,"shares":66,"price":245.63,"value":16211.58,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":2515,"source":{"system":"sec-edgar","filing":"0001179110-17-004109","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017004109/edgar.xml","form_type":"4"}},{"id":4396613,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-03-07T16:54:19.000Z","date":"2017-03-04","kind":"tax_withholding","acquired":false,"shares":72,"price":245.63,"value":17685.36,"ownership":{"direct":true},"balance_after":2581,"source":{"system":"sec-edgar","filing":"0001179110-17-004109","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017004109/edgar.xml","form_type":"4"}},{"id":4467873,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-02-03T19:43:09.000Z","date":"2017-02-01","kind":"exercise","acquired":false,"shares":238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents performance-based restricted share units (\"PSUs\") which vested on February 1, 2017, following certification of achievement by issuer of certain performance criteria. Each PSU represented a contingent right to receive ordinary shares of the Issuer equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and Reporting Person."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents performance-based restricted share units (\"PSUs\") which vested on February 1, 2017, following certification of achievement by issuer of certain performance criteria. Each PSU represented a contingent right to receive ordinary shares of the Issuer equal to the product of the applicable performance multiple and the target number of shares underlying the PSU, as set forth in the award agreement between the Issuer and Reporting Person."}],"balance_after":0,"derivative":{"exercise_price":229.32,"exercise_date":"2017-02-01","expiration_date":"2017-02-01","underlying":"Ordinary Shares","underlying_shares":238},"source":{"system":"sec-edgar","filing":"0001179110-17-001708","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017001708/edgar.xml","form_type":"4"}},{"id":4467872,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-02-03T19:43:09.000Z","date":"2017-02-01","kind":"tax_withholding","acquired":false,"shares":92,"price":229.32,"value":21097.44,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc."}],"balance_after":2653,"source":{"system":"sec-edgar","filing":"0001179110-17-001708","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017001708/edgar.xml","form_type":"4"}},{"id":4467871,"issuer":{"id":149298,"kind":"organization","name":"Allergan plc","symbol":"AGN"},"owners":[{"id":26199,"kind":"person","name":"DArecca James","position":1,"cik":"0001583903","reported_name":"DArecca James","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF ACCOUNTING OFFICER"}}],"security":"Ordinary Shares, par value $0.0001","published_at":"2017-02-03T19:43:09.000Z","date":"2017-02-01","kind":"grant","acquired":true,"shares":238,"price":229.32,"value":54578.16,"ownership":{"direct":true},"balance_after":2745,"source":{"system":"sec-edgar","filing":"0001179110-17-001708","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578845/000117911017001708/edgar.xml","form_type":"4"}}]}